Translational Deal Radar
Surface emerging therapeutic programs worth manual BD and IP review before they become widely discussed. This tool is built for early prioritization, not legal or investment conclusions.
Built on ClinicalTrials.gov activity and conservative patent-linkage heuristics. Every asset still requires manual BD, IP, and scientific review before any outreach or strategic conclusion.
The public preview is intentionally limited to 20 Cell Therapy assets. The remaining radar is reserved for paid access.
Cell therapy
CAR-T, CAR-NK, TCR-T, TIL, and adjacent cell-therapy programs.
20
Assets visible in the free preview today.
Manual review first
Outputs preserve uncertainty and are designed to support expert diligence, not replace it.
Which early clinical assets may be worth licensing, investing in, or monitoring?
Translational Deal Radar identifies academic and early-biotech therapeutic assets entering human development, then links trial activity to patent, institution, investigator, and sponsor signals. The first edition focuses on academic and early-biotech oncology cell-therapy programs.
Target users
- Pharma BD teams sourcing early assets and licensing candidates
- Venture capital firms and biotech investors
- Biotech scouts and early-stage program evaluators
- University technology-transfer offices
- Strategic consultants supporting BD and investment diligence
- Early-stage biotech founders tracking competitive programs
How teams use this module
- Find academic cell-therapy programs entering Phase 1 from leading cancer centers
- Identify investigator–inventor overlap signals that may indicate IP-linked programs
- Monitor translational assets from universities and hospitals before they attract broad attention
- Track new trial starts by small biotechs entering a modality or indication space
- Generate custom target, modality, or institution scans for BD or investment sourcing
Cell Therapy Deal Radar
Academic and early-biotech oncology cell-therapy assets screened for trial momentum, translational relevance, and conservative BD follow-up value.
Radiopharma Deal Radar
Radioligand and radiopharma programs where trial activity and IP signal clarity matter for sourcing. Request a custom scan via the form below.
Gene Editing Deal Radar
A future screening view for CRISPR, base-editing, and engineered platform programs entering meaningful translational milestones. Register interest below.
Autologous tumor-infiltrating lymphocytes
Autologous tumor-infiltrating lymphocytes is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Inge Marie Svane, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Inge Marie Svane · Phase1
View asset summaryTumor biopsy
Tumor biopsy is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Gustave Roussy, Cancer Campus, Grand Paris, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Gustave Roussy, Cancer Campus, Grand Paris · Na
View asset summaryScreening Platform
Screening Platform is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at GlaxoSmithKline, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
GlaxoSmithKline · Phase2
View asset summaryReceive Cell Therapy Radar Updates by Email
The public preview shows 20 assets. Subscribe to receive radar updates by email, choose CSV interests, and request paid-access follow-up.